ALK and non-small cell lung carcinoma: In the pivotal phase 2 ALTA trial of patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) that progressed on crizotinib, brigatinib 180 mg qd with a seven-day lead-in at 90 mg was associated with an independent review committee-assessed confirmed objective response rate (ORR) of 56 % and median progression-free survival (PFS) of 16.7 months with a median follow-up of 24 months [4].